Why the study?
Despite numerous international guidelines for Kawasaki disease, there has been no comparison of them, and optimal treatment for high-risk and refractory disease lacks evidence.
Comparison
Comparison of international treatment guidelines for Kawasaki disease
Design
Review
Authors
Loading...
Guideline comparison in KD reveals consistent IVIG-aspirin core but divergent adjunct recommendations; leaves open evidence-based optimization.
This review highlights the consensus on first-line IVIG and aspirin for Kawasaki disease across international guidelines, while identifying discrepancies in aspirin dosing and the management of IVIG-resistant and high-risk patients.
Buda et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: